5-Day Sell-Off Sends Sonnet BioTherapeutics Stock Down -70%
Sonnet BioTherapeutics (SONN) stock hit day 5 of a continuous streak of days with losses, with cumulative losses over this period amounting to a -70% return. The company has lost about $11 Mil in value over the last 5 days, with its current market capitalization at about $4.9 Mil. The stock remains 13.7% below its value at the end of 2024. This compares with year-to-date returns of 16.1% for the S&P 500.
Sonnet BioTherapeutics’ recent streak saw shares plummet as its approved business combination converted the biotech into Hyperliquid Strategies, a crypto-treasury vehicle. This abrupt pivot from drug development to a crypto-linked valuation, culminating in a stock suspension and transition to the ‘PURR’ ticker, ignited intense selling amid investor uncertainty.
What is the point? Sustained weakness can be more than noise. It often signals shifting sentiment or deeper concerns. A multi-day losing streak may warn of further downside, or present an opportunity to buy if fundamentals are intact.For quick background, SONN develops a platform for single or bispecific biologic medicines, with a lead candidate targeting non-small cell lung and head and neck cancers using a fully human interleukin 12.
Comparing SONN Stock Returns With The S&P 500
- Palantir At 80x Earnings: What Revenue Growth Rate Justifies The Valuation?
- Should You Pay Attention To Chevron Stock’s Momentum?
- What Is Happening With Caterpillar Stock?
- What Can Trigger Microsoft Stock’s Slide?
- Is Microsoft Stock A Trap Or A Missed Opportunity?
- Earn 9.6% Today or Buy BSX 30% Cheaper – It’s a Win-Win
The following table summarizes the return for SONN stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | SONN | S&P 500 |
|---|---|---|
| 1D | -59.4% | 0.2% |
| 5D (Current Streak) | -74.0% | 1.9% |
| 1M (21D) | -74.9% | -0.2% |
| 3M (63D) | -59.7% | 5.9% |
| YTD 2025 | -13.7% | 16.1% |
| 2024 | -89.5% | 23.3% |
| 2023 | -93.1% | 24.2% |
| 2022 | -80.1% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 50 S&P constituents with 3 days or more of consecutive gains and 61 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 15 | 37 |
| 4D | 9 | 24 |
| 5D | 13 | 0 |
| 6D | 1 | 0 |
| 7D or more | 12 | 0 |
| Total >=3 D | 50 | 61 |
Key Financials for Sonnet BioTherapeutics (SONN)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0.1 Mil | $18,626 |
| Operating Income | $-18.8 Mil | $-11.8 Mil |
| Net Income | $-18.8 Mil | $-7.4 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-4.2 Mil | $-3.8 Mil |
| Net Income | $-3.5 Mil | $-3.8 Mil |
The losing streak SONN stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.